Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + levamlodipine + atorvastatin
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telmitrend-S (CKD-330) is a triple-combination small molecule drug developed by Chong Kun Dang Pharmaceutical for the management of patients with both essential hypertension and hyperlipidemia. It consists of telmisartan, an angiotensin II receptor blocker (ARB); levamlodipine (the S-enantiomer of amlodipine), a calcium channel blocker (CCB); and atorvastatin, an HMG-CoA reductase inhibitor (statin). This fixed-dose combination is designed to simplify complex treatment regimens for patients with multiple cardiovascular risk factors, thereby improving medication adherence. The drug was approved in South Korea in 2020 following clinical trials demonstrating its efficacy and safety compared to dual-combination or monotherapy components.
- Brand names
- Telmitrend-S
- Other names
- telmisartan + s-amlodipine + atorvastatintelmisartan + levamlodipine + atorvastatin calcium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on telmisartan + levamlodipine + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + levamlodipine + atorvastatin.